CA2277544A1 - Identification d'inhibiteurs de la proteine tyrosine-kinase 2 - Google Patents

Identification d'inhibiteurs de la proteine tyrosine-kinase 2 Download PDF

Info

Publication number
CA2277544A1
CA2277544A1 CA002277544A CA2277544A CA2277544A1 CA 2277544 A1 CA2277544 A1 CA 2277544A1 CA 002277544 A CA002277544 A CA 002277544A CA 2277544 A CA2277544 A CA 2277544A CA 2277544 A1 CA2277544 A1 CA 2277544A1
Authority
CA
Canada
Prior art keywords
pyk2
compound
ability
activity
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002277544A
Other languages
English (en)
Inventor
Le T. Duong
Gideon A. Rodan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2277544A1 publication Critical patent/CA2277544A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des dosages de composés qui se lient à la protéine tyrosine-kinase 2 ou qui modulent son activité. Ces ligands sont utilisés pour le traitement de l'ostéoporose et/ou de l'inflammation.
CA002277544A 1997-02-11 1998-02-09 Identification d'inhibiteurs de la proteine tyrosine-kinase 2 Abandoned CA2277544A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3756097P 1997-02-11 1997-02-11
US60/037,560 1997-02-11
PCT/US1998/002797 WO1998035056A1 (fr) 1997-02-11 1998-02-09 Identification d'inhibiteurs de la proteine tyrosine-kinase 2

Publications (1)

Publication Number Publication Date
CA2277544A1 true CA2277544A1 (fr) 1998-08-13

Family

ID=21895000

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002277544A Abandoned CA2277544A1 (fr) 1997-02-11 1998-02-09 Identification d'inhibiteurs de la proteine tyrosine-kinase 2

Country Status (5)

Country Link
EP (1) EP0968304A1 (fr)
JP (1) JP2001512309A (fr)
AU (1) AU6163398A (fr)
CA (1) CA2277544A1 (fr)
WO (1) WO1998035056A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2289122C (fr) 1997-02-18 2009-04-21 Lxr Biotechnology Inc. Systeme d'expression de promoteur de bak
WO2000040971A1 (fr) * 1998-12-31 2000-07-13 Sugen, Inc. Pyk2 (raftk) et inflammation
US6861442B1 (en) 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
EP1630559A3 (fr) * 1998-12-30 2006-06-07 Sugen, Inc. PYK2 (RAFTK) et inflammation
AU5951201A (en) * 2000-05-04 2001-11-12 Univ Yale High density protein arrays for screening of protein activity
CA2426508A1 (fr) * 2000-10-23 2002-05-16 Bristol-Myers Squibb Company Modulateurs de tyrosine kinase de bruton et intermediaires de tyrosine kinase de bruton et leurs procedes d'identification et d'utilisation dans le traitement et la prevention de l'osteoporose et d'etats pathologiques connexes
US20040266771A1 (en) * 2001-06-29 2004-12-30 Alain Moussy Use of tyrosine kinase inhibitors for treating bone loss
ES2266553T3 (es) 2001-06-29 2007-03-01 Ab Science Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias.
ES2274075T3 (es) 2001-06-29 2007-05-16 Ab Science Utilizacion de inhibidores de c-kit para tratar enfermedades inflamatorias intestinales (eii).
DE60223063T2 (de) 2001-06-29 2008-07-17 Ab Science C-kit inhibitoren
EP1401413B1 (fr) 2001-06-29 2006-11-22 AB Science Utilisation d'inhibiteurs de tyrosine kinase dans le traitement de maladies allergiques
US20050170431A1 (en) * 2003-02-28 2005-08-04 Plexxikon, Inc. PYK2 crystal structure and uses
BRPI0512342A (pt) * 2004-06-21 2008-03-04 Pharmacia & Upjohn Co Llc métodos para aumento ósseo

Also Published As

Publication number Publication date
AU6163398A (en) 1998-08-26
EP0968304A1 (fr) 2000-01-05
JP2001512309A (ja) 2001-08-21
WO1998035056A1 (fr) 1998-08-13

Similar Documents

Publication Publication Date Title
AU697142B2 (en) Protein tyrosine kinases named Rse
Pasqualini et al. Contrasting roles for integrin beta 1 and beta 5 cytoplasmic domains in subcellular localization, cell proliferation, and cell migration.
US7446176B2 (en) 12 human secreted proteins
US20040018980A1 (en) Novel FIZZ proteins
CA2277544A1 (fr) Identification d'inhibiteurs de la proteine tyrosine-kinase 2
CA2331239A1 (fr) Structure, fabrication et utilisation de l'hereguline
IE920317A1 (en) Domains of extracellular region of human platelet-derived¹growth factor receptor polypeptides
CA2111573C (fr) Materiel de cadherine et methodes
WO1997027873A1 (fr) Anticorps destines a moduler la transmigration des neutrophiles induite par cd47
TWI356097B (en) Ccn1 compositions and methods
US20030044899A1 (en) Isolated laminin 10
US6210913B1 (en) Modulation of integrin-mediated signal transduction
David et al. Integrins interact with focal adhesions through multiple distinct pathways
NZ524342A (en) Receptor in the EDb fibronectin domain
KR20040031031A (ko) 면역 관련 질환 치료용 조성물 및 치료 방법
JP3755649B2 (ja) 細胞接着、伸張、および剥離活性を示すペプチドおよびその誘導体
EP2843048B1 (fr) NOUVEAU LIGAND DE L'INTÉGRINE alpha9beta1 ET SES UTILISATIONS
WO2000059940A2 (fr) Gene et proteine lies au facteur de croissance d'origine plaquettaire
Madden et al. A peptide derived from neutrophil inhibitory factor (NIF) blocks neutrophil adherence to endothelial cells
US5874234A (en) Assay for a novel mammalian protein associated with uncontrolled cell division
KR100481796B1 (ko) 섬유아세포의 αｖβ5 인테그린과 특이적으로 결합하는βｉｇ-ｈ3 단백질 유래 펩타이드
JPH10174591A (ja) 可溶性組換えαｖβ３付着受容体
CA2277028A1 (fr) Proteine tyrosine-kinase 2 (pyk2), acides nucleiques et methode de detection
US20170145391A1 (en) TRUNCATED VARIANT OF THE MAMMALIAN TARGET FOR RAPAMYCIN (mTOR) PROTEIN
Shen The Role of Galpha13 in Integrin Signaling and Function

Legal Events

Date Code Title Description
FZDE Dead